Inductive Bio
Inductive Bio builds an AI/ML virtual chemistry lab platform for small-molecule drug discovery, offering ADMET prediction models (Beacon-1), a virtual lab interface (Compass), an AI chemistry assistant (Indy), and integrated lab services (ADME-One) to biopharma R&D teams.
- Company typePrivate
- Founded2023
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Inductive Bio does
Inductive Bio is a New York-based, venture-backed AI/ML company founded in 2023 that builds a virtual chemistry lab platform for small-molecule drug discovery. Its product suite is anchored by Compass (the virtual lab interface), Beacon-1 (a class of ADMET prediction models trained on a pre-competitive industry consortium and fine-tuned to each customer's chemical space), Indy (an AI chemistry assistant that automates assay QC, SAR analysis, and analog enumeration), and Digital Organs (toxicity models trained on billions of drug-organ interaction data points). Layered on top are three service offerings: Embedded Experts (where Inductive's chemists and DMPK scientists operate the virtual lab alongside partner teams), ADME-One™ (a co-developed Tier 1 ADME + human PK projection platform with Ginkgo Bioworks Datapoints and Tangible Scientific, priced several times lower than industry standard), and End-to-End Chemistry (AI-informed synthesis and testing through CRO partners including Enamine, Ginkgo, and Tangible Scientific).
The company sells primarily through a direct enterprise sales motion targeting biopharma R&D teams, with "Book a Demo" CTAs gating quote-based Compass subscriptions, Embedded Experts engagements, and ADME-One services; revenue is supplemented by a non-dilutive ARPA-H grant (up to $21M). Customers include venture-backed biotechs (Rapport Therapeutics, Nested Therapeutics, Arrakis Therapeutics, Belharra Therapeutics, Aleksia Therapeutics, Nexo Therapeutics, Architect Therapeutics, Tenvie) and enterprise biopharma (Denali Therapeutics, Amgen). The company is independently validated by first-place finishes in consecutive open-world ADMET blind competitions (Polaris 2025, OpenADMET 2026 with ExpansionRx), SOC 2 compliance, and partnerships including CAS Connections and the ARPA-H CATALYST DATALMAP project.
Inductive Bio firmographics
Firmographics- Name
- Inductive Bio
- Legal name
- Inductive Bio, Inc.
- Website
- https://inductive.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Inductive Bio builds an AI/ML virtual chemistry lab platform for small-molecule drug discovery, offering ADMET prediction models (Beacon-1), a virtual lab interface (Compass), an AI chemistry assistant (Indy), and integrated lab services (ADME-One) to biopharma R&D teams.
- Ownership category
- akta.pro rank
Inductive Bio industry classification
Industry- Product category
- AI-Driven Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Inductive Bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Inductive Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Compass Platform Subscriptions: Recurring software subscription revenue from the Compass virtual lab platform, which provides direct access to run virtual experiments, review predictions in real time, and decide what to synthesize. The platform is used by biopharma partners to optimize active small-molecule programs.
- Embedded Experts Professional Services: Fee-based professional services where Inductive's chemistry, computational chemistry, and DMPK experts operate as an extension of the customer's team, running experiments and delivering curated compound ideas tailored to design strategy. Acts as AI-powered drug discovery consultants.
- ADME-One Tier 1 ADME Service: Integrated ADME service offering priced several times lower than the industry standard, combining high-throughput Tier 1 ADME assays with AI-driven human PK projection. Delivered via the Ginkgo Bioworks Datapoints and Tangible Scientific partnership. Returns results in days rather than weeks.
- Government Grant Funding (ARPA-H): Non-dilutive government funding from the Advanced Research Projects Agency for Health (ARPA-H) CATALYST program. Up to $21M award to lead the DATAMAP project developing AI drug toxicity models. This supplements commercial revenue with grant-based research funding.
- End-to-End Chemistry CRO Services: Service revenue from end-to-end program acceleration through partnerships with select CROs (Enamine, Ginkgo Bioworks, Tangible Scientific), providing AI-informed synthesis and testing in a tight feedback loop with the virtual lab.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Quote-based enterprise pricing via "Book a Demo" |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels8 records
Inductive Bio product offering
Product offeringCore offering
Inductive Bio provides an AI/ML-powered virtual lab platform for small molecule drug discovery. Its Compass software, Beacon-1 ADMET prediction models, and Indy AI chemistry assistant enable biopharma teams to run millions of in silico experiments, predict ADMET properties, and prioritize compounds for synthesis. Layered on top are Embedded Experts professional services, the ADME-One integrated ADME platform (co-developed with Ginkgo Bioworks Datapoints and Tangible Scientific), and End-to-End Chemistry services delivered via select CRO partners.
Product overview
Inductive Bio operates a unified virtual chemistry lab platform composed of multiple integrated products. The Compass platform serves as the core interface (virtual lab bench) that gives teams direct access to run virtual experiments, review predictions, and decide what to synthesize in real time. Compass is powered by Beacon-1 (the gold-standard ADMET model class trained on a pre-competitive consortium data) and is assisted by Indy (an AI chemistry assistant that automates QC, data mining, and rational analog enumeration). The pre-competitive Data Consortium supplies the diverse ADMET data foundation used to train and fine-tune Beacon-1. Digital organs are a parallel product capability trained on billions of drug-organ interaction data points to predict safety in humans. Three service offerings layer on top of the software: Embedded Experts (dedicated medicinal chemistry, computational chemistry, and DMPK support from Inductive's scientists operating the virtual lab alongside partners); ADME-One™ (a fully integrated Tier 1 ADME + human PK projection platform co-developed with Ginkgo Datapoints and Tangible Scientific); and End-to-End Chemistry (AI-informed synthesis and testing via select CRO partners to close the loop between virtual and wet lab). The architecture is platform-plus-modules, with Compass as the central user-facing product and Beacon-1, Indy, the Consortium, Digital organs, and the three service lines as its integrated modules and offerings.
Differentiator
Problem solved
Functional benefit
Brands
- Compass: Compass is Inductive Bio's virtual lab software interface that allows drug discovery teams to run virtual experiments, review predictions in real time, and decide what compounds to synthesize; it is the interface to Inductive's ADMET and PK models.
- Beacon-1
- Indy
- ADME-One™
- Consortium
- Embedded Experts
Products and services
- Compass
Quantifiable outcome
- Consecutive 1st place finishes in the world's largest ADMET benchmarks (Polaris 2025, OpenADMET-ExpansionRx 2026)
- +7 more outcomes
Companies that use Inductive Bio
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles2 records
Inductive Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability12 records
Feature7 records
Inductive Bio partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and flagship.
- CAS (American Chemical Society)coreTechnology integration as part of the CAS Connections framework. CAS launched CAS Connections, an integration framework that embeds its scientific knowledge collection and CAS Newton agentic AI into existing R&D workflow platforms, with Inductive Bio as one of the first wave of collaborators. The framework supports deployment via APIs, Model Context Protocol, and AI platform integrations for tools such as Anthropic's Claude and Microsoft Copilot.
- AmgencoreCollaborating on the DATAMAP project (Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven Predictions) under the ARPA-H CATALYST program. Amgen advises on development, real-world context of use in drug development, and potential applications to novel therapies. Amgen plans to submit an investigational new drug application (IND) to the FDA using the technology developed in the project.
- Cincinnati Children's Hospital Medical CentercoreResearch collaborator on the DATAMAP project under the ARPA-H CATALYST program. The institution participates in a $21M federal project called CATALYST to enhance drug safety testing using human organoids and AI. Involved in developing more accurate models for predicting drug toxicity and reducing animal testing.
- Baylor College of MedicinecoreResearch collaborator on the DATAMAP project under the ARPA-H CATALYST program. Part of a multi-institution collaboration to generate biological data from organoids, ex-vivo human tissue, and microphysiological systems for AI model training.
- Torch BiocoreTorch Bio is a University of Michigan Medical School spinout company that collaborates on the DATAMAP project under the ARPA-H CATALYST program. Involved in generating biological data from advanced human model systems for AI toxicity model development.
- Ginkgo Bioworks (Datapoints)flagshipStrategic partnership to deploy AI-driven lab-in-the-loop drug discovery workflows across the biopharma industry. Combines Ginkgo Datapoints' rapid ADME profiling with Inductive Bio's model-driven chemistry design platform. In May 2026, the partnership was deepened with the co-development and launch of ADME-One™, a fully integrated ADME platform. Ginkgo Datapoints handles all five Tier 1 ADME assays in its automated Boston laboratory.
- Tangible ScientificflagshipStrategic partnership to deploy AI-driven lab-in-the-loop drug discovery. Tangible Scientific's API-enabled compound management platform handles compound intake, plating, real-time tracking, and management for ADME-One orders. Co-develops the ADME-One platform with Ginkgo Bioworks Datapoints and Inductive Bio. Based in Natick, MA with same-day courier service to Boston-area partners.
- Denali TherapeuticscoreOne of Inductive Bio's initial industry partners established when the company emerged from stealth in December 2023. Collaborating on the ML platform to speed up compound optimization by improving ADMET property predictions.
- EnaminecoreEnd-to-End Chemistry partner. Inductive partners with Enamine and other select drug discovery CROs to help rapidly test best ideas. Compounds move from AI-powered predictions in the virtual lab to traditional synthetic chemistry and high-throughput DMPK assays at Enamine.
- Aleksia TherapeuticscoreStrategic research collaboration. Co-developed a probabilistic human dose projection case study that built a framework translating preclinical data into predicted human dose distributions while explicitly propagating uncertainty. The case study triaged three advanced candidates during late lead optimization, producing a clear ranking that the leaderboard couldn't. Co-authors Amy Hart and Eunice Park from Aleksia collaborated with Gaby Gerlach and Nic Pabon from Inductive Bio.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Inductive Bio competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Public computational chemistry and molecular simulation platform with broad pharma/biotech adoption. Directly comparable in offering ADMET prediction, virtual screening, and physics-based drug discovery software to biopharma, with a much larger platform and established enterprise customer base.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology, chemistry, and ML for small molecule and target identification. Comparable in targeting biopharma customers with AI-enabled discovery workflows, but operates at significantly larger scale with internal wet lab infrastructure.
- Isomorphic Labs: Alphabet-owned AI drug discovery spinout of DeepMind. Comparable in applying state-of-the-art ML to small molecule discovery and protein structure prediction, with massive capital backing and pharma partnerships (Eli Lilly, Novartis).
Direct peers
- Insilico Medicine: Clinical-stage AI drug discovery company with end-to-end platform spanning target identification through clinical development. Directly comparable in offering AI/ML-driven small molecule drug discovery services to biopharma, with similar target customer base and business model.
- Exscientia: AI-driven precision medicine company with end-to-end drug discovery platform and clinical-stage assets. Directly comparable in offering AI-based small molecule design and ADMET optimization services to biopharma partners, though recently restructured and focused on oncology.
- Atomwise: AI-driven small molecule drug discovery company using structure-based AtomNet platform for hit identification and lead optimization. Comparable in serving biopharma with AI/ML-powered compound design, with similar technology focus and customer profile.
- Terray Therapeutics: AI-driven small molecule discovery company combining wet lab data generation with ML models. Directly comparable in using proprietary experimental data to train foundation models for chemistry, and Edward Williams previously worked there before joining Inductive Bio.
- Iambic Therapeutics: AI-driven drug discovery company developing clinical and preclinical small molecule candidates. Directly comparable in using ML/AI for small molecule design with platform technology serving biopharma, and competes in similar ADMET and lead optimization space.
- XtalPi: AI-driven drug discovery company combining quantum physics, AI, and robotics for small molecule R&D. Comparable in offering AI-powered drug discovery services to biopharma with significant CRO/scale-up capabilities and a similar model of integrated AI + wet lab workflow.
Emerging players
- BigHat Biosciences: AI/ML-driven antibody design platform with wet lab integration for ML-guided design cycles. Comparable in applying ML to drug discovery with lab-in-the-loop methodology, founded by Mark DePristo who serves on Inductive Bio's advisory board, and uses similar integration of AI with experimental chemistry.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Inductive Bio social profiles
Digital presenceInductive Bio compliance and trust
Trust signalCompliance1 record
Inductive Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inductive Bio leadership team
Management profileNumber of profiles
Profiles11 records
Inductive Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inductive Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inductive Bio
What does Inductive Bio do?
Inductive Bio provides an AI/ML-powered virtual lab platform for small molecule drug discovery. Its Compass software, Beacon-1 ADMET prediction models, and Indy AI chemistry assistant enable biopharma teams to run millions of in silico experiments, predict ADMET properties, and prioritize compounds for synthesis. Layered on top are Embedded Experts professional services, the ADME-One integrated ADME platform (co-developed with Ginkgo Bioworks Datapoints and Tangible Scientific), and End-to-End Chemistry services delivered via select CRO partners.
Is Inductive Bio a public or private company?
Inductive Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inductive Bio founded?
Inductive Bio was founded in 2023. It employs 1 to 10 people.
Where is Inductive Bio based?
Inductive Bio is headquartered in San Francisco, United States, in the North America region.
How does Inductive Bio make money?
Five revenue lines are on record. Compass Platform Subscriptions are the primary driver. The others are embedded Experts Professional Services, ADME-One Tier 1 ADME Service, government Grant Funding (ARPA-H) and end-to-End Chemistry CRO Services.
Who are Inductive Bio's main competitors?
Broad incumbents on record are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Direct peers are Insilico Medicine, Exscientia, Atomwise, Terray Therapeutics, Iambic Therapeutics and XtalPi. BigHat Biosciences is listed as an emerging player.
Does Inductive Bio have an API?
Yes. Inductive Bio's Compass models are integrated seamlessly into the tools partners already use via API, enabling access to run virtual experiments, review predictions, and decide what to synthesize in real time. The web application is accessible at app.inductive.bio/login. The CAS Connections integration framework (which embeds CAS scientific content and CAS Newton agentic AI into Inductive Bio's R&D platform) supports deployment via APIs, Model Context Protocol (MCP), and AI platform integrations.
What industry is Inductive Bio in?
Inductive Bio's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.